CO5190679A1 - Sal disfosfato de un derivado de 4"-sustituido-9-desoxo- 9a-aza-9a-homoeritromicina y su composicion farmaceutica - Google Patents
Sal disfosfato de un derivado de 4"-sustituido-9-desoxo- 9a-aza-9a-homoeritromicina y su composicion farmaceuticaInfo
- Publication number
- CO5190679A1 CO5190679A1 CO00045176A CO00045176A CO5190679A1 CO 5190679 A1 CO5190679 A1 CO 5190679A1 CO 00045176 A CO00045176 A CO 00045176A CO 00045176 A CO00045176 A CO 00045176A CO 5190679 A1 CO5190679 A1 CO 5190679A1
- Authority
- CO
- Colombia
- Prior art keywords
- mammals
- diphosphate salt
- methyl
- free base
- homoeritromycin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical class OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 abstract 4
- 239000012458 free base Substances 0.000 abstract 3
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 206010037075 Protozoal infections Diseases 0.000 abstract 2
- 230000001580 bacterial effect Effects 0.000 abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 239000003904 antiprotozoal agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 125000006308 propyl amino group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Esta invención se refiere a una nueva sal difosfato cristalina de (2R, 3S, 4R, 5R, 8R, 10R, 11R, 12S, 13S, 14R)-13-[[2,6-didesoxi-3-C-metil-3-0-metil-4-C [(propilamino)metil]-a-L-ribo-hexopiranosil]oxi]-2-etil-3,4,10-trihidroxi-3, 5, 8, 10, 12, 14-hexametil-11-[[3, 4, 6- tridesoxi-3-(dimetilamino)-ß-D-xilo-hexopiranosil]oxi]-1-oxa-6-azaciclopentadecan-15-ona que es útil como agente antibacteriano y antiprotozoario en mamíferos. Esta invención también se refiere a composiciones farmacéuticas que contienen la base libre de la sal difosfato y a los procedimientos de tratamiento de infecciones bacterianas y protozoarias en mamíferos, mediante la administración de la base libre de la sal difosfato a mamíferos que requieren dicho tratamiento. La base libre de la sal difosfato de la presente invención posee una potente actividad contra diversas infecciones bacterianas y protozoarias cuando se administra por vía parenteral a mamíferos.<EMI FILE="00045176_1" ID="1" IMF=JPEG >
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14168199P | 1999-06-30 | 1999-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5190679A1 true CO5190679A1 (es) | 2002-08-29 |
Family
ID=22496734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00045176A CO5190679A1 (es) | 1999-06-30 | 2000-06-16 | Sal disfosfato de un derivado de 4"-sustituido-9-desoxo- 9a-aza-9a-homoeritromicina y su composicion farmaceutica |
Country Status (42)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6465437B1 (en) * | 1999-06-30 | 2002-10-15 | Pfizer Inc. | Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition |
| US6791660B1 (en) * | 2002-02-12 | 2004-09-14 | Seiko Epson Corporation | Method for manufacturing electrooptical device and apparatus for manufacturing the same, electrooptical device and electronic appliances |
| US7468428B2 (en) | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| EP2736915A1 (en) | 2011-07-27 | 2014-06-04 | Farma GRS, d.o.o. | New crystalline forms of tulathromycin |
| CN106008622A (zh) * | 2016-08-02 | 2016-10-12 | 海门慧聚药业有限公司 | 泰拉霉素新晶型及其制备 |
| CN110885351A (zh) * | 2019-12-17 | 2020-03-17 | 海门慧聚药业有限公司 | 泰拉霉素磷酸盐的晶型及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU43006B (en) * | 1981-03-06 | 1989-02-28 | Pliva Pharm & Chem Works | Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof |
| US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| SI9011409A (en) * | 1990-07-18 | 1995-10-31 | Pliva Pharm & Chem Works | O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them |
| HN1998000086A (es) * | 1997-06-11 | 1999-03-08 | Pfizer Prod Inc | Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos. |
| JP2003512290A (ja) * | 1997-09-10 | 2003-04-02 | メルク エンド カムパニー インコーポレーテッド | 家畜抗菌剤としての８ａ−アザライド |
| UA70972C2 (uk) * | 1998-11-20 | 2004-11-15 | Пфайзер Продактс Інк. | 13-членні азаліди і їх застосування як антибіотиків |
| CA2372206C (en) * | 1999-05-18 | 2006-01-10 | Pfizer Products Inc. | Novel crystalline forms of a macrolide antibiotic |
| US6465437B1 (en) * | 1999-06-30 | 2002-10-15 | Pfizer Inc. | Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition |
-
2000
- 2000-05-18 US US09/574,160 patent/US6465437B1/en not_active Expired - Fee Related
- 2000-06-01 HN HN2000000090A patent/HN2000000090A/es unknown
- 2000-06-06 PA PA20008496901A patent/PA8496901A1/es unknown
- 2000-06-13 IL IL14640888A patent/IL146408A0/xx unknown
- 2000-06-13 SK SK1892-2001A patent/SK286243B6/sk not_active IP Right Cessation
- 2000-06-13 EE EEP200100699A patent/EE05068B1/xx not_active IP Right Cessation
- 2000-06-13 CN CNA200710199182XA patent/CN101220067A/zh active Pending
- 2000-06-13 BR BR0012091-0A patent/BR0012091A/pt not_active IP Right Cessation
- 2000-06-13 JP JP2001507850A patent/JP2003503506A/ja active Pending
- 2000-06-13 PT PT00931491T patent/PT1189913E/pt unknown
- 2000-06-13 AP APAP/P/2001/002370A patent/AP2001002370A0/en unknown
- 2000-06-13 MX MXPA02000058A patent/MXPA02000058A/es active IP Right Grant
- 2000-06-13 PL PL352900A patent/PL201891B1/pl unknown
- 2000-06-13 EA EA200101178A patent/EA004235B1/ru not_active IP Right Cessation
- 2000-06-13 EP EP00931491A patent/EP1189913B1/en not_active Expired - Lifetime
- 2000-06-13 OA OA1200100329A patent/OA11965A/en unknown
- 2000-06-13 HU HU0201693A patent/HUP0201693A3/hu unknown
- 2000-06-13 KR KR10-2001-7016939A patent/KR100442508B1/ko not_active IP Right Cessation
- 2000-06-13 DE DE60017399T patent/DE60017399T2/de not_active Expired - Fee Related
- 2000-06-13 CA CA002376748A patent/CA2376748C/en not_active Expired - Fee Related
- 2000-06-13 TR TR2001/03834T patent/TR200103834T2/xx unknown
- 2000-06-13 WO PCT/IB2000/000785 patent/WO2001002414A1/en active IP Right Grant
- 2000-06-13 AT AT00931491T patent/ATE286906T1/de not_active IP Right Cessation
- 2000-06-13 CN CN00809635A patent/CN1358188A/zh active Pending
- 2000-06-13 AU AU49439/00A patent/AU772277B2/en not_active Ceased
- 2000-06-13 CZ CZ20014571A patent/CZ20014571A3/cs unknown
- 2000-06-13 UA UA2001129148A patent/UA71013C2/uk unknown
- 2000-06-13 YU YU88701A patent/YU88701A/sh unknown
- 2000-06-13 ES ES00931491T patent/ES2233380T3/es not_active Expired - Lifetime
- 2000-06-16 CO CO00045176A patent/CO5190679A1/es not_active Application Discontinuation
- 2000-06-26 UY UY26221A patent/UY26221A1/es not_active Application Discontinuation
- 2000-06-27 PE PE2000000645A patent/PE20010287A1/es not_active Application Discontinuation
- 2000-06-28 TN TNTNSN00143A patent/TNSN00143A1/fr unknown
- 2000-06-28 MY MYPI20002923 patent/MY133360A/en unknown
- 2000-06-28 MA MA26011A patent/MA26745A1/fr unknown
- 2000-06-28 AR ARP000103255A patent/AR035551A1/es not_active Application Discontinuation
- 2000-06-28 GT GT200000105AK patent/GT200000105AA/es unknown
- 2000-06-28 GT GT200000105A patent/GT200000105A/es unknown
- 2000-06-30 EC EC2000003555A patent/ECSP003555A/es unknown
-
2001
- 2001-11-13 IS IS6159A patent/IS6159A/is unknown
- 2001-11-20 BG BG106123A patent/BG65587B1/bg unknown
- 2001-12-11 HR HR20010919A patent/HRP20010919B1/xx not_active IP Right Cessation
- 2001-12-19 NO NO20016221A patent/NO20016221D0/no not_active Application Discontinuation
- 2001-12-20 ZA ZA200110453A patent/ZA200110453B/xx unknown
-
2002
- 2002-08-12 US US10/218,154 patent/US6861412B2/en not_active Expired - Fee Related
-
2004
- 2004-05-06 US US10/840,529 patent/US7297682B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9814601A (pt) | "macrólidos" | |
| PT952835E (pt) | Metodo de tratamento de doenca cardiaca causada por chlamidia pneumoniae | |
| AP9801253A0 (en) | 9-Oxime erythromycin derivatives. | |
| SI0729473T1 (en) | Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use | |
| PL307137A1 (en) | Derivatives of 16-member cyclic antibiotic macrolydes | |
| CO5190679A1 (es) | Sal disfosfato de un derivado de 4"-sustituido-9-desoxo- 9a-aza-9a-homoeritromicina y su composicion farmaceutica | |
| ZA932048B (en) | Alkylthio alkyl avermectins are active antiparasitic agents. | |
| JPS61251696A (ja) | 新規化合物，その製法及びそれを含む医薬組成物 | |
| PT1133511E (pt) | Novos intermediarios e processo para preparar um agente antibiotico macrolido a partir deles | |
| HRP20030907B1 (en) | Pharmaceutical composition based on macrolides for topical application in ophthalmology | |
| RS82504A (en) | Isostructural pseudopolymorphs of 9- deoxo-9a-aza-9a-methil- 9a- homoerythromycin a | |
| WO2003089446A3 (en) | 23-o-substituted 5-o-mycaminosyltylonide derivatives | |
| CA2332686A1 (en) | Novel 13 and 14-membered antibacterial and prokinetic macrolides and their intermediates | |
| AP9801235A0 (en) | Erythromycin derivatives. | |
| EP0416327A3 (en) | Chemical derivatives of antibiotics ll-e19020 alpha and beta | |
| WO2004000864A3 (en) | 11-c-substituted ketolides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |